BMRN Q2 2019 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$388M+4.0% YoY

Gross Profit

$310M80.0% margin

Operating Income

-$41M-10.7% margin

Net Income

-$37M-9.7% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-3.2%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$63M

Stock-Based Comp.

$40M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$1.4B

Stockholders' Equity

$3.0B

Cash & Equivalents

$308M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$388M	$373M	+4.0%
Gross Profit	$310M	$294M	+5.6%
Operating Income	-$41M	-$25M	-63.7%
Net Income	-$37M	-$17M	-122.9%

Revenue Segments

Product

$379M50%

Product Four

$123M16%

Product Three

$113M15%

Product Two

$98M13%

Product Seven

$19M2%

Product Six

$15M2%

Product One

$6M1%

Product Five

$5M1%

Geographic Segments

UNITED STATES

$169M44%

Europe

$120M31%

Rest Of World

$52M13%

Latin America

$46M12%